All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance
During the7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to María Díez Campelo, University Hospital of Salamanca, Salamanca, ES. We asked, What is new for MDS with del(5q)?
What is new for MDS with del(5q)?
Lenalidomide reduces risk of transfusion dependency in lower-risk MDS: Interim results of the Sintra-REV trial
The therapeutic goal for patients with lower-risk myelodysplastic syndrome (MDS) is to improve bone marrow function and reduce the...
Editorial theme | Immune dysregulation and genetic mutations associated with MDS pathogenesis
The pathogenesis of myelodysplastic syndromes (MDS) is heterogeneous, involving inflammation, cytokines, growth factors, the accumulation of genetic damage,...
Subscribe to get the best content related to MDS delivered to your inbox